⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125961 | 1.00 | — | — | |
| SCHEMBL2782776 | 0.71 | — | — | |
| SCHEMBL5510804 | 0.71 | — | — | |
| SCHEMBL5100810 | 0.71 | — | — | |
| SCHEMBL845658 | 0.67 | — | — | |
| SCHEMBL5133418 | 0.64 | — | — | |
| SCHEMBL5133421 | 0.64 | — | — | |
| SCHEMBL3540559 | 0.62 | — | — | |
| SCHEMBL3538842 | 0.62 | — | — | |
| SCHEMBL4663455 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964938-B2 | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists | CELON PHARMA S.A. (PL) | 2024-04-23 | — | — | US | disclosed |
| EP-3737470-B9 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | Celon Pharma Sa (PL) | 2024-03-13 | — | — | EP | disclosed |
| CN-111757770-B | 3-Phenyl-4-hexynoic acid derivatives as GPR40 agonists | 赛隆制药股份公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-3737470-B1 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | Celon Pharma Sa (PL) | 2022-12-14 | — | — | EP | disclosed |
| US-20200399198-A1 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | CELON PHARMA S.A. (PL) | 2020-12-24 | — | — | US | disclosed |
| EP-3737470-A1 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | CELON PHARMA S.A. (PL) | 2020-11-18 | — | — | EP | disclosed |
| CN-111757770-A | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists | 赛隆制药股份公司 | 2020-10-09 | — | — | CN | disclosed |
| WO-2019134984-A1 | 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS | CELON PHARMA S.A. (PL) | 2019-07-11 | — | — | WO | disclosed |
| EP-0969828-B1 | BUTYRATE PRODRUGS DERIVED FROM LACTIC ACID | VERTEX PHARMA (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-0863866-B1 | BUTYRATE PRODRUGS OF LACTIC ACID | VERTEX PHARMA (US) | 2001-05-02 | — | — | EP | disclosed |
| US-6225350-B1 | ADMINISTERING BUTYRATE PRODRUG FOR THERAPY OF CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS, INC. | 2001-05-01 | — | — | US | disclosed |
| EP-0969828-A1 | BUTYRATE PRODRUGS DERIVED FROM LACTIC ACID | Vertex Pharmaceuticals Incorporated (US) | 2000-01-12 | — | — | EP | disclosed |
| US-5912269-A | SICKLE CELL SYNDROME, ANTICARCIOGENIC AGENTS | VERTEX PHARMACEUTICALS, INC. (US) | 1999-06-15 | — | — | US | disclosed |
| US-5883123-A | GAMMA GLOBIN AND FETAL HEMOGLOBIN, SICKLE CELL SYNDROME AND THALASSEMIA SYNDROME | VERTEX PHARMACEUTICALS, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5880152-A | INFLAMMATORY BOWEL DISEASE | VERTEX PHARMACEUTICALS, INC. (US) | 1999-03-09 | — | — | US | disclosed |
| WO-1998040064-A1 | BUTYRATE PRODRUGS DERIVED FROM LACTIC ACID | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-09-17 | — | — | WO | disclosed |
| EP-0863866-A1 | BUTYRATE PRODRUGS OF LACTIC ACID | Vertex Pharmaceuticals Incorporated (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997012855-A1 | BUTYRATE PRODRUGS OF LACTIC ACID | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-04-10 | — | — | WO | disclosed |